Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

I am bullish on Novo Nordisk due to its 62% global GLP-1 market share and dominant Ozempic sales, supporting long-term leadership. Novo Nordisk's diversified GLP-1 portfolio, including Rybelsus ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and ...

The Caron Treatment Center, a nonprofit rehab facility located about 70 miles from Philadelphia, has begun prescribing low doses of semaglutide, the active ingredient in Novo Nordisk's Ozempic and ...